PL3126383T3 - Zmodyfikowany łańcuch J - Google Patents

Zmodyfikowany łańcuch J

Info

Publication number
PL3126383T3
PL3126383T3 PL15718304T PL15718304T PL3126383T3 PL 3126383 T3 PL3126383 T3 PL 3126383T3 PL 15718304 T PL15718304 T PL 15718304T PL 15718304 T PL15718304 T PL 15718304T PL 3126383 T3 PL3126383 T3 PL 3126383T3
Authority
PL
Poland
Prior art keywords
chain
modified
Prior art date
Application number
PL15718304T
Other languages
English (en)
Inventor
Bruce Keyt
Leonard George Presta
Fen Zhang
Ramesh Baliga
Original Assignee
Igm Biosciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Igm Biosciences, Inc. filed Critical Igm Biosciences, Inc.
Publication of PL3126383T3 publication Critical patent/PL3126383T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL15718304T 2014-04-03 2015-04-02 Zmodyfikowany łańcuch J PL3126383T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461974738P 2014-04-03 2014-04-03
PCT/US2015/024149 WO2015153912A1 (en) 2014-04-03 2015-04-02 Modified j-chain
EP15718304.7A EP3126383B8 (en) 2014-04-03 2015-04-02 Modified j-chain

Publications (1)

Publication Number Publication Date
PL3126383T3 true PL3126383T3 (pl) 2019-08-30

Family

ID=52998235

Family Applications (2)

Application Number Title Priority Date Filing Date
PL19165016T PL3560954T3 (pl) 2014-04-03 2015-04-02 Zmodyfikowany łańcuch J
PL15718304T PL3126383T3 (pl) 2014-04-03 2015-04-02 Zmodyfikowany łańcuch J

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL19165016T PL3560954T3 (pl) 2014-04-03 2015-04-02 Zmodyfikowany łańcuch J

Country Status (21)

Country Link
US (5) US10400038B2 (pl)
EP (3) EP4011910A1 (pl)
JP (2) JP6744822B2 (pl)
KR (3) KR102380402B1 (pl)
CN (2) CN106459213B (pl)
AU (3) AU2015240595B2 (pl)
BR (1) BR112016022841B1 (pl)
CA (1) CA2944647C (pl)
DK (2) DK3126383T3 (pl)
ES (2) ES2717704T3 (pl)
HU (2) HUE055693T2 (pl)
IL (3) IL292311A (pl)
MX (2) MX2019008359A (pl)
NZ (1) NZ725568A (pl)
PL (2) PL3560954T3 (pl)
PT (2) PT3560954T (pl)
RU (2) RU2021134101A (pl)
SG (2) SG10201909716RA (pl)
SI (2) SI3560954T1 (pl)
WO (1) WO2015153912A1 (pl)
ZA (1) ZA201606906B (pl)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2671558C2 (ru) 2013-06-14 2018-11-02 Псайоксус Терапьютикс Лимитед Режим введения и составы для аденовирусов типа в
JP6721505B2 (ja) 2013-09-05 2020-07-15 アイジーエム バイオサイエンシズ インコーポレイテッド 定常領域が修飾された（ｃｏｎｓｔａｎｔ ｃｈａｉｎ ｍｏｄｉｆｉｅｄ）二重特異性五価及び六価Ｉｇ−Ｍ抗体
AU2014338864C1 (en) 2013-10-25 2020-07-16 Akamis Bio Limited Oncolytic adenoviruses armed with heterologous genes
JP2017512208A (ja) 2014-02-10 2017-05-18 アイジーエム バイオサイエンス， インコーポレイテッド ＩｇＡ多重特異性結合分子
IL292311A (en) 2014-04-03 2022-06-01 Igm Biosciences Inc J-chain qualified
PT3247728T (pt) 2015-01-20 2020-07-16 Igm Biosciences Inc Moléculas de ligação do recetor da superfamília do fator de necrose tumoral (fnt) e utilização das mesmas
KR102357312B1 (ko) * 2015-03-04 2022-02-03 아이쥐엠 바이오사이언스 인코포레이티드 Ｃｄ20 결합 분자 및 그의 용도
WO2016154593A1 (en) 2015-03-25 2016-09-29 Igm Biosciences, Inc. Multi-valent hepatitis b virus antigen binding molecules and uses thereof
WO2016168758A1 (en) 2015-04-17 2016-10-20 Igm Biosciences, Inc. Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof
EP3824903A1 (en) 2015-09-30 2021-05-26 IGM Biosciences Inc. Binding molecules with modified j-chain
EP3356401B1 (en) * 2015-09-30 2020-06-24 IGM Biosciences, Inc. Binding molecules with modified j-chain
EA201891022A1 (ru) 2015-12-17 2019-01-31 Псайоксус Терапьютикс Лимитед Вирус, кодирующий антитело к комплексу tcr или фрагмент указанного антитела
JP6979971B2 (ja) * 2016-05-09 2021-12-15 アイジーエム バイオサイエンシズ インコーポレイテッド 抗ｐｄ−ｌ１抗体
CN119614520A (zh) 2016-08-29 2025-03-14 阿卡米斯生物公司 携带双特异性t细胞衔接器的腺病毒
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
SG11201907299XA (en) 2017-02-08 2019-09-27 Dragonfly Therapeutics Inc Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
IL268755B2 (en) 2017-02-20 2025-12-01 Dragonfly Therapeutics Inc Proteins that bind her2, nkg2d, and cd16
US11401337B2 (en) 2017-04-07 2022-08-02 Igm Biosciences, Inc. Modified human IgM constant regions for modulation of complement-dependent cytolysis effector function
GB201801614D0 (en) 2018-01-31 2018-03-14 Psioxus Therapeutics Ltd Formulation
EA202091887A1 (ru) 2018-02-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Комбинированная терапия рака с применением мультиспецифических связывающих белков, которые активируют естественные клетки-киллеры
DK3749346T3 (da) 2018-02-08 2024-09-09 Dragonfly Therapeutics Inc Antistof variable domænekombinationer rettet mod nkg2d-receptoren
WO2019164930A1 (en) 2018-02-20 2019-08-29 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use
CN111787951B (zh) * 2018-03-01 2025-06-17 Igm生物科学股份有限公司 影响IgM血清半衰期的IgM Fc和J链突变
US12378318B2 (en) 2018-08-08 2025-08-05 Dragonfly Therapeutics, Inc. Proteins binding NKG2D, CD16 and a tumor-associated antigen
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
WO2020033630A1 (en) 2018-08-08 2020-02-13 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
US20220162312A1 (en) * 2019-01-28 2022-05-26 WuXi Biologics Ireland Limited Novel bispecific cd3/cd20 polypeptide complexes
WO2021022113A1 (en) * 2019-07-31 2021-02-04 The Wistar Institute Of Anatomy And Biology Multivalent dna antibody constructs and use thereof
MX2022001934A (es) 2019-08-15 2022-03-11 Igm Biosciences Inc Moleculas de union multimericas inmunoestimuladoras.
WO2021034646A1 (en) * 2019-08-17 2021-02-25 Igm Biosciences, Inc. Multimeric bispecific anti-cd123 binding molecules and uses thereof
KR20220050166A (ko) * 2019-08-23 2022-04-22 아이쥐엠 바이오사이언스 인코포레이티드 Igm 글리코변이체
CN114616031A (zh) * 2019-09-19 2022-06-10 Igm生物科学股份有限公司 对靶标密度高的细胞的选择性增强的多聚体抗体
AU2020353182A1 (en) * 2019-09-27 2022-04-14 Beijing Starmab Biomed Technology Ltd Monospecific and multi-specific antibodies
BR112022021392A2 (pt) 2020-04-22 2022-12-06 Igm Biosciences Inc Moléculas de ligação multiméricas de agonista de pd-1
MX2022013944A (es) 2020-05-06 2022-11-30 Dragonfly Therapeutics Inc Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), cumulo de diferenciacion (cd16) y miembro a de la familia de dominios de lectina tipo c 12 (clec12a).
AR124414A1 (es) 2020-12-18 2023-03-22 Century Therapeutics Inc Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
JP2024508894A (ja) 2021-03-03 2024-02-28 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｎｋｇ２ｄ、ｃｄ１６、及び腫瘍関連抗原に結合する多特異性結合タンパク質を使用して癌を治療する方法
WO2022256740A1 (en) 2021-06-04 2022-12-08 Curia Ip Holdings, Llc Polymeric fusion proteins and compositions for inducing an immune response against infection
WO2023196995A1 (en) 2022-04-07 2023-10-12 Repertoire Immune Medicines, Inc. T cell receptor multimers and uses thereof
US12600801B2 (en) 2022-07-11 2026-04-14 Fred Hutchinson Cancer Center Single-domain antibodies that bind ROR1

Family Cites Families (147)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8719963D0 (en) 1987-08-24 1987-09-30 Cattaneo A Recombinant dna products
US5831034A (en) 1987-11-13 1998-11-03 Hermann Katinger Human monoclonal anti-HIV-I-antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
SG46445A1 (en) 1990-01-26 1998-02-20 Immunomedics Inc Vaccines against cancer and infectious diseases
DK0642585T3 (da) 1992-05-18 2006-05-15 Genentech Inc Aktiviering af oligomeriserende receptorer ved anvendelse af fusionerede receptorligander
US6476198B1 (en) 1993-07-13 2002-11-05 The Scripps Research Institute Multispecific and multivalent antigen-binding polypeptide molecules
UA40577C2 (uk) 1993-08-02 2001-08-15 Мерк Патент Гмбх Біспецифічна молекула, що використовується для лізису пухлинних клітин, спосіб її одержання, моноклональне антитіло (варіанти), фармацевтичний препарат, фармацевтичний набір (варіанти), спосіб видалення пухлинних клітин
AU697387C (en) 1994-09-16 2006-03-02 Austin Research Institute Cancer and Anti-inflammatory Syndicate No 1 Polypeptides with Fc binding ability
US5874540A (en) 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
IL111196A0 (en) 1994-10-07 1994-12-29 Yeda Res & Dev Peptides and pharmaceutical compositions comprising them
US6808709B1 (en) 1994-12-30 2004-10-26 The Regents Of The University Of California Immunoglobulins containing protection proteins and their use
US6165463A (en) 1997-10-16 2000-12-26 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
MX9708008A (es) 1995-04-19 1998-03-31 Polymun Scient Immunbio Forsch Anticuerpos monoclonales contra vih-1 y vacunas hechas de los mismos.
US20050003431A1 (en) 1996-08-16 2005-01-06 Wucherpfennig Kai W. Monovalent, multivalent, and multimeric MHC binding domain fusion proteins and conjugates, and uses therefor
US8212004B2 (en) 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
AU740918B2 (en) * 1997-01-10 2001-11-15 Plantibodies Corporation Novel epithelial tissue targeting agent
US6045774A (en) * 1997-01-10 2000-04-04 Epicyte Pharmaceutical Inc. J chain polypeptide targeting molecule linked to an imaging agent
US20040009166A1 (en) 1997-04-30 2004-01-15 Filpula David R. Single chain antigen-binding polypeptides for polymer conjugation
WO1999054484A1 (en) 1998-04-20 1999-10-28 The Regents Of The University Of California Modified immunoglobulin molecules and methods for use thereof
DE60043626D1 (de) 1999-01-07 2010-02-11 Zymogenetics Inc Verfahren zur therapeutischen Verwendung von löslichen rezeptoren BR43X2
WO2000061637A1 (en) 1999-04-14 2000-10-19 Smithkline Beecham Corporation Erythropoietin receptor antibodies
CA2375912C (en) 1999-06-09 2014-03-11 Immunomedics, Inc. Immunotherapy of autoimmune disorders using antibodies which target b-cells
WO2001012820A1 (en) 1999-08-17 2001-02-22 Health Research Institute Genetic system and self-cleaving inteins derived therefrom, bioseparations and protein purification employing same, and methods for determining critical, generalizable amino acid residues for varying intein activity
IL148079A0 (en) 1999-08-24 2002-09-12 Medarex Inc Human ctla-4 antibodies and compositions containing the same
US20050287153A1 (en) 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
CN101289511A (zh) 2000-04-11 2008-10-22 杰南技术公司 多价抗体及其应用
US20020168367A1 (en) * 2000-04-28 2002-11-14 Planet Biotechnology Incorporated Novel immunoadhesins for treating and preventing viral and bacterial diseases
AU2001257445B2 (en) 2000-04-28 2006-11-02 Planet Biotechnology, Inc. Immunoadhesin for the prevention of rhinovirus infection
MXPA02011092A (es) 2000-05-10 2004-08-19 David A Sirbasku Composiciones y metodos para demostrar la regulacion del sistema inmune secretor del crecimiento de la celula de cancer que responde a la hormona esteroidea.
CA2414272A1 (en) 2000-07-10 2002-01-17 Novartis Ag Bifunctional molecules and vectors complexed therewith for targeted gene delivery
JP2004514423A (ja) 2000-09-07 2004-05-20 シュライバー，　ジョン　アール． トランスジェニックｘｅｎｏｍｏｕｓｅ（登録商標）から獲得されるｐｅｕｄｏｍｏｎａｓａｅｒｕｇｉｎｏｓａｌｐｓに対するヒト抗体
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7138496B2 (en) 2002-02-08 2006-11-21 Genetastix Corporation Human monoclonal antibodies against human CXCR4
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
AU2002248571B2 (en) * 2001-03-07 2007-01-18 Merck Patent Gmbh Expression technology for proteins containing a hybrid isotype antibody moiety
US7402312B2 (en) 2001-04-13 2008-07-22 Human Genome Sciences, Inc. Antibodies to vascular endothelial growth factor 2 (VEGF-2)
US20050129616A1 (en) 2001-05-25 2005-06-16 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
NZ513418A (en) 2001-08-07 2004-04-30 Univ Massey Vaccine comprising proteins from mycobacterium paratuberculosis
WO2003034903A2 (en) 2001-10-23 2003-05-01 Psma Development Company, L.L.C. Psma antibodies and protein multimers
KR101033196B1 (ko) 2002-02-14 2011-05-09 이뮤노메딕스, 인코오포레이티드 항-ｃｄ20 항체 및 그 융합 단백질 및 이들의 이용방법
US7282567B2 (en) 2002-06-14 2007-10-16 Immunomedics, Inc. Monoclonal antibody hPAM4
WO2003074566A2 (en) 2002-03-01 2003-09-12 Immunomedics, Inc. Rs7 antibodies
KR101017732B1 (ko) 2002-03-01 2011-02-28 이뮤노메딕스, 인코오포레이티드 내재화 항-ｃｄ74 항체 및 그 이용방법
BR0309254A (pt) 2002-04-12 2005-03-01 Medarex Inc Uso de um anticorpo anti-ctla-4
US7601351B1 (en) 2002-06-26 2009-10-13 Human Genome Sciences, Inc. Antibodies against protective antigen
NZ537277A (en) 2002-07-18 2008-04-30 Crucell Holland Bv Recombinant production of mixtures of antibodies
CA2494310A1 (en) 2002-08-01 2004-02-12 Immunomedics, Inc. Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
US20040156826A1 (en) 2002-09-27 2004-08-12 Fernando Dangond Treatment of patients with multiple sclerosis based on gene expression changes in central nervous system tissues
US7541440B2 (en) 2002-09-30 2009-06-02 Immunomedics, Inc. Chimeric, human and humanized anti-granulocyte antibodies and methods of use
US20050014932A1 (en) 2003-05-15 2005-01-20 Iogenetics, Llc Targeted biocides
AR044388A1 (es) 2003-05-20 2005-09-07 Applied Molecular Evolution Moleculas de union a cd20
EP1626992B1 (en) 2003-05-23 2010-06-02 Crucell Holland B.V. Production of recombinant igm in per.c6 cells
ATE490787T1 (de) 2003-07-15 2010-12-15 Chugai Pharmaceutical Co Ltd Produktion von igm durch transformierte zellen und verfahren zur quantifizierung dieser igm- produktion
EP2216342B1 (en) 2003-07-31 2015-04-22 Immunomedics, Inc. Anti-CD19 antibodies
US8147832B2 (en) 2003-08-14 2012-04-03 Merck Patent Gmbh CD20-binding polypeptide compositions and methods
US7803914B2 (en) 2003-10-09 2010-09-28 Chugai Seiyaku Kabushiki Kaisha Methods for stabilizing protein solutions
DE602004030811D1 (de) 2003-10-16 2011-02-10 Micromet Ag Multispezifische deimmunisierte cd3-bindende moleküle
FR2861255B1 (fr) 2003-10-24 2006-02-17 Centre Nat Rech Scient Mammifere non-humain transgenique pour la region constante de la chaine lourde des immunoglobulines humaines de classe a et ses applications.
EP1706425A2 (en) 2003-12-05 2006-10-04 John R. Schreiber Human anti-pseudomonas-aeruginosa antibodies derived from transgenic xenomouse®
US20050249723A1 (en) 2003-12-22 2005-11-10 Xencor, Inc. Fc polypeptides with novel Fc ligand binding sites
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
CN101098889A (zh) 2004-11-05 2008-01-02 盘林京有限公司 抗体导致的细胞膜损伤
US7251164B2 (en) 2004-11-10 2007-07-31 Innovative Silicon S.A. Circuitry for and method of improving statistical distribution of integrated circuits
EP1833848A2 (en) 2004-12-09 2007-09-19 Lajolla Institute for Allergy and Immunology Novel tnf receptor regulatory domain
ES2665422T3 (es) 2005-03-03 2018-04-25 Immunomedics Inc. Anticuerpos L243 humanizados
US8349332B2 (en) 2005-04-06 2013-01-08 Ibc Pharmaceuticals, Inc. Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
KR20080031001A (ko) 2005-06-02 2008-04-07 아스트라제네카 아베 Ｃｄ20에 대한 항체 및 그의 용도
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
AR056142A1 (es) 2005-10-21 2007-09-19 Amgen Inc Metodos para generar el anticuerpo igg monovalente
JP2009521474A (ja) 2005-12-21 2009-06-04 メディミューン，エルエルシー ＥｐｈＡ２ＢｉＴＥ分子およびその使用
BRPI0711586A2 (pt) 2006-05-15 2011-11-16 Immunonomedics, Inc. método para tratamento de infecção por hiv em um indivìduo, método para imagem latente detectar ou diagnosticar a infecção por hiv em um indivìduo, composição
US8268635B2 (en) 2006-05-19 2012-09-18 Antonio Ferrante Methods of identifying agents that selectively activate p38 and/or NKkB signaling
WO2007146968A2 (en) 2006-06-12 2007-12-21 Trubion Pharmaceuticals, Inc. Single-chain multivalent binding proteins with effector function
CA2914170C (en) 2006-09-08 2018-10-30 Abbvie Bahamas Ltd. Interleukin-13 binding proteins
US9382327B2 (en) 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use
CA2668208C (en) 2006-11-02 2017-09-12 Daniel J. Capon Hybrid immunoglobulins with moving parts
US20080145420A1 (en) 2006-12-13 2008-06-19 Simon Michael R HUMAN SECRETORY IgA FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASES
EP2087111A2 (en) 2007-03-19 2009-08-12 Medimmune Limited Polypeptide variants
WO2008135963A2 (en) 2007-05-02 2008-11-13 Hemogem Inc. Fibrinogen for treatment of bleeding in trauma and platelet disorders
WO2009013620A2 (en) 2007-06-11 2009-01-29 Erasmus University Medical Center Rotterdam Homologous recombination
EP2195342A1 (en) 2007-09-07 2010-06-16 Ablynx N.V. Binding molecules with multiple binding sites, compositions comprising the same and uses thereof
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
CA2706700A1 (en) 2007-11-08 2009-05-14 Cytimmune Sciences, Inc. Compositions and methods for generating antibodies
EP2254592B1 (en) 2008-02-28 2019-06-05 Dako Denmark A/S Mhc multimers in borrelia diagnostics and disease
ITTO20080313A1 (it) 2008-04-22 2009-10-23 Marco Colombatti Anticorpo monoclonale isolato o suo frammento legante l'antigene specifico di membrana della prostata, suoi coniugati e suoi usi
WO2010006286A2 (en) 2008-07-11 2010-01-14 Sea Lane Biotechnologies, Llc Constructs and libraries comprising antibody surrogate kappa light chain sequences
WO2010037402A1 (en) 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
DK2356270T3 (da) 2008-11-07 2016-12-12 Fabrus Llc Kombinatoriske antistofbiblioteker og anvendelser deraf
EP2509997B1 (en) 2009-12-07 2017-08-30 i2 Pharmaceuticals, Inc. Conjugates comprising an antibody surrogate scaffold with improved pharmacokinetic properties
CN102958942A (zh) 2009-12-29 2013-03-06 新兴产品开发西雅图有限公司 异二聚体结合蛋白及其应用
TW201129384A (en) 2010-02-10 2011-09-01 Immunogen Inc CD20 antibodies and uses thereof
WO2011100538A1 (en) 2010-02-11 2011-08-18 Alexion Pharmaceuticals, Inc. Therapeutic methods using an ti-cd200 antibodies
AU2011318567B2 (en) 2010-10-19 2017-02-09 Mayo Foundation For Medical Education And Research Human antibodies and diagnostic and therapeutic uses thereof for the treatment of neurological disease
WO2012088290A2 (en) 2010-12-22 2012-06-28 Abbott Laboratories Tri-variable domain binding proteins and uses thereof
AU2012328917B2 (en) 2011-10-24 2017-05-25 Abbvie Inc. Bispecific immunobinders directed against TNF and IL-17
GB201122047D0 (en) 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
WO2013087912A1 (en) 2011-12-16 2013-06-20 Synthon Biopharmaceuticals B.V. Compounds and methods for treating inflammatory diseases
TWI606064B (zh) 2012-02-08 2017-11-21 Ｉｇｍ生物科技公司 細胞死亡誘導分子（ｃｄｉｍ）結合蛋白類及彼等之用途
EP3427747A1 (en) 2012-04-05 2019-01-16 Gottfried Himmler Secretory immunoglobulin complex
EP3305323B1 (en) 2012-04-17 2021-02-17 Mayo Foundation for Medical Education and Research Human antibodies and specific binding sequences thereof for use in stroke and ischemia or ischemic conditions
WO2013188870A2 (en) 2012-06-15 2013-12-19 Beth Israel Deaconess Medical Center, Inc. IgA CD4i ANTIBODIES AND METHODS OF TREATMENT USING SAME
CN103570821A (zh) * 2012-07-27 2014-02-12 北京智飞绿竹生物制药有限公司 粘蛋白-1抗原性多肽及其作为肿瘤疫苗的用途
CN104684928A (zh) 2012-08-02 2015-06-03 Jn生物科学有限责任公司 通过半胱氨酸突变和μ尾端多聚化的抗体或融合蛋白
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
US10066238B2 (en) 2013-02-11 2018-09-04 University Of Louisville Research Foundation, Inc. Methods for producing antibodies
US9487773B2 (en) 2013-03-01 2016-11-08 Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa Cell-based methods for coupling protein interactions and binding molecule selection
US20160152686A1 (en) 2013-03-13 2016-06-02 Bristol-Myers Squibb Company Fibronectin based scaffold domains linked to serum albumin or moiety binding thereto
GB201311487D0 (en) 2013-06-27 2013-08-14 Alligator Bioscience Ab Bispecific molecules
US20150038682A1 (en) 2013-08-02 2015-02-05 Jn Biosciences Llc Antibodies or fusion proteins multimerized via homomultimerizing peptide
JP6721505B2 (ja) 2013-09-05 2020-07-15 アイジーエム バイオサイエンシズ インコーポレイテッド 定常領域が修飾された（ｃｏｎｓｔａｎｔ ｃｈａｉｎ ｍｏｄｉｆｉｅｄ）二重特異性五価及び六価Ｉｇ−Ｍ抗体
WO2015037000A1 (en) 2013-09-11 2015-03-19 Compugen Ltd Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases
BR112016015140A2 (pt) 2013-12-30 2018-01-23 Epimab Biotherapeutics Inc. imunoglobulina com fabs in-tandem e usos das mesmas
SG10201806025TA (en) 2014-01-16 2018-08-30 Mario Umberto Francesco Mondelli Neutralizing human monoclonal antibodies against hepatitis b virus surface antigen
JP2017512208A (ja) 2014-02-10 2017-05-18 アイジーエム バイオサイエンス， インコーポレイテッド ＩｇＡ多重特異性結合分子
US20150259420A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
IL292311A (en) 2014-04-03 2022-06-01 Igm Biosciences Inc J-chain qualified
PT3247728T (pt) 2015-01-20 2020-07-16 Igm Biosciences Inc Moléculas de ligação do recetor da superfamília do fator de necrose tumoral (fnt) e utilização das mesmas
KR102357312B1 (ko) 2015-03-04 2022-02-03 아이쥐엠 바이오사이언스 인코포레이티드 Ｃｄ20 결합 분자 및 그의 용도
WO2016154593A1 (en) 2015-03-25 2016-09-29 Igm Biosciences, Inc. Multi-valent hepatitis b virus antigen binding molecules and uses thereof
WO2016168758A1 (en) 2015-04-17 2016-10-20 Igm Biosciences, Inc. Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof
FI3319936T3 (fi) 2015-07-12 2026-03-12 Hangzhou Dac Biotech Co Ltd Silloituslinkkereitä soluun sitoutuvien molekyylien konjugoimiseksi
EP3356401B1 (en) 2015-09-30 2020-06-24 IGM Biosciences, Inc. Binding molecules with modified j-chain
EP3824903A1 (en) 2015-09-30 2021-05-26 IGM Biosciences Inc. Binding molecules with modified j-chain
JP6979971B2 (ja) 2016-05-09 2021-12-15 アイジーエム バイオサイエンシズ インコーポレイテッド 抗ｐｄ−ｌ１抗体
JP2019530640A (ja) 2016-07-20 2019-10-24 アイジーエム バイオサイエンシズ インコーポレイテッド 多量体ｏｘ４０結合分子及びその使用
EP3487298A4 (en) 2016-07-20 2020-03-11 IGM Biosciences, Inc. MULTIMERE CD137 / 4-1BB-BINDING MOLECULES AND USES THEREOF
AU2017300647A1 (en) 2016-07-20 2019-02-07 Igm Biosciences, Inc. Multimeric GITR binding molecules and uses thereof
EP3496536A4 (en) 2016-07-20 2020-02-12 IGM Biosciences, Inc. MULTIMERE CD40-BINDING MOLECULES AND USES THEREOF
US11401337B2 (en) 2017-04-07 2022-08-02 Igm Biosciences, Inc. Modified human IgM constant regions for modulation of complement-dependent cytolysis effector function
AU2019224136A1 (en) 2018-02-26 2020-09-10 Igm Biosciences, Inc. Use of a multimeric anti-DR5 binding molecule in combination with a chemotherapeutic agent for treating cancer
CN111787951B (zh) 2018-03-01 2025-06-17 Igm生物科学股份有限公司 影响IgM血清半衰期的IgM Fc和J链突变
KR20210083260A (ko) 2018-10-23 2021-07-06 아이쥐엠 바이오사이언스 인코포레이티드 다가 IgM- 및 IgA-Fc 기반 결합 분자
US20220106398A1 (en) 2019-02-08 2022-04-07 Igm Biosciences, Inc. Anti-gitr antigen-binding domains and uses thereof
MX2022001934A (es) 2019-08-15 2022-03-11 Igm Biosciences Inc Moleculas de union multimericas inmunoestimuladoras.
WO2021034646A1 (en) 2019-08-17 2021-02-25 Igm Biosciences, Inc. Multimeric bispecific anti-cd123 binding molecules and uses thereof
KR20220050166A (ko) 2019-08-23 2022-04-22 아이쥐엠 바이오사이언스 인코포레이티드 Igm 글리코변이체
CN114616031A (zh) 2019-09-19 2022-06-10 Igm生物科学股份有限公司 对靶标密度高的细胞的选择性增强的多聚体抗体
IL293739A (en) 2020-01-06 2022-08-01 Igm Biosciences Inc Highly sialic acid-modified multimeric binding compounds
BR112022021392A2 (pt) 2020-04-22 2022-12-06 Igm Biosciences Inc Moléculas de ligação multiméricas de agonista de pd-1
JP2023526224A (ja) 2020-05-12 2023-06-21 アイジーエム バイオサイエンシズ インコーポレイテッド がんを治療するための、がん治療薬との組合せでの多量体抗ｄｒ５結合分子の使用
EP4188951A4 (en) 2020-07-27 2024-08-28 IGM Biosciences, Inc. Multimeric coronavirus binding molecules and uses thereof
US20240002526A1 (en) 2020-11-17 2024-01-04 Igm Biosciences, Inc. Uses of effector cell engaging molecules with moieties of differing potencies
JP2024508709A (ja) 2021-02-17 2024-02-28 アイジーエム バイオサイエンシズ インコーポレイテッド 抗ｃｄ１２３結合分子及びその使用法
US20220267415A1 (en) 2021-02-17 2022-08-25 The Board Of Regents Of The University Of Texas System Multimeric sars-cov-2 binding molecules and uses thereof

Also Published As

Publication number Publication date
JP7062025B2 (ja) 2022-05-02
RU2016141579A3 (pl) 2018-12-26
BR112016022841B1 (pt) 2023-09-26
IL248151A0 (en) 2016-11-30
RU2016141579A (ru) 2018-05-10
EP3560954B1 (en) 2021-08-04
MX2016012880A (es) 2017-05-12
US10400038B2 (en) 2019-09-03
NZ725568A (en) 2022-10-28
HUE042829T2 (hu) 2019-07-29
KR102380402B1 (ko) 2022-03-31
EP3126383B8 (en) 2019-02-27
US20190002566A1 (en) 2019-01-03
CN106459213A (zh) 2017-02-22
JP2017512815A (ja) 2017-05-25
PL3560954T3 (pl) 2021-12-13
KR20220044377A (ko) 2022-04-07
SG11201608194VA (en) 2016-10-28
CN112759650B (zh) 2024-10-01
BR112016022841A2 (pt) 2017-10-17
MX366588B (es) 2019-07-15
EP3560954A1 (en) 2019-10-30
RU2021134101A (ru) 2022-03-22
DK3560954T3 (da) 2021-09-06
DK3126383T3 (en) 2019-04-01
US20170183409A1 (en) 2017-06-29
AU2020201347B2 (en) 2022-03-10
ZA201606906B (en) 2021-07-28
CN112759650A (zh) 2021-05-07
SI3560954T1 (sl) 2021-11-30
IL278350B (en) 2022-06-01
IL292311A (en) 2022-06-01
EP4011910A1 (en) 2022-06-15
WO2015153912A1 (en) 2015-10-08
AU2020201347A1 (en) 2020-03-12
MX2019008359A (es) 2019-09-16
US10975147B2 (en) 2021-04-13
AU2015240595A1 (en) 2016-11-03
US20170283510A1 (en) 2017-10-05
ES2717704T3 (es) 2019-06-24
JP2020114828A (ja) 2020-07-30
AU2015240595B2 (en) 2020-02-27
CA2944647C (en) 2025-07-08
US20230279111A1 (en) 2023-09-07
JP6744822B2 (ja) 2020-08-19
KR20230155600A (ko) 2023-11-10
CN106459213B (zh) 2020-12-01
PT3126383T (pt) 2019-03-22
EP3126383B1 (en) 2018-12-19
ES2887299T3 (es) 2021-12-22
AU2022201585A1 (en) 2022-03-31
US11555075B2 (en) 2023-01-17
SG10201909716RA (en) 2019-11-28
BR112016022841A8 (pt) 2018-06-12
CA2944647A1 (en) 2015-10-08
KR20160142345A (ko) 2016-12-12
RU2761118C2 (ru) 2021-12-06
US20200190190A1 (en) 2020-06-18
PT3560954T (pt) 2021-09-07
US9951134B2 (en) 2018-04-24
SI3126383T1 (sl) 2019-05-31
EP3126383A1 (en) 2017-02-08
HUE055693T2 (hu) 2021-12-28

Similar Documents

Publication Publication Date Title
PT3560954T (pt) Cadeia j modificada
DK3134402T3 (da) 4-amino-imidazoquinolinforbindelser
DK3006072T3 (da) Karadgang
DK3211743T3 (da) Ø-til-netværk-omskiftningsfremgangsmåde
PL3171891T3 (pl) Sposób
DK3222714T3 (da) Phytasemutanter
DK3119396T3 (da) Muscarinreceptoragonister
DK3110442T3 (da) Modificerede meningokok-fhbp-polypeptider
DK4242916T3 (da) Forstøver
DE112015005642A5 (de) Laschenkette
DK3183340T3 (da) Termolabile exonukleaser
EP4011484C0 (en) CARBONIC ANHYDRASE OF THERMOVIBRIO AMMONIFICANS
DE112015001664A5 (de) Betätigungsaktuator
DK3094579T3 (da) Bånd-på-bånd transportør
DK3154703T3 (da) Fuldkappe-snekkecentrifuge
DE112015005041A5 (de) Gargerätevorrichtung
BR112016026476A2 (pt) Bloco de corrente
DK3110439T3 (da) Pcsk9-vacciner
DE102014000623A8 (de) Halbhohlnietelement
DK3009858T3 (da) Skyradar
DE112015000933A5 (de) Laschenkette
DE202014005655U8 (de) llluminationsvorrichtung
DE112015001633A5 (de) Betätigungsaktuator
DK3447493T3 (da) Proteinrettede ortologer
ES1133830Y (es) Columbario